Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.

摘要: We report the final results of a prospectively randomized study that compared combination epirubicin, cisplatin and protracted venous infusion fluorouracil (5-FU) (ECF regimen) with standard 5-FU, doxorubicin methotrexate (FAMTX) in previously untreated patients advanced oesophagogastric cancer. Between 1992 1995, 274 adenocarcinoma or undifferentiated carcinoma were from eight oncology centres UK analysed for response survival. The overall rate was 46% (95% confidence interval (CI), 37-55%) ECF, 21% CI, 13-28%) FAMTX (P = 0.00003). median survival 8.7 months ECF 6.1 0.0005). 2-year rates 14% 8-20%) arm, 5% 2-10%) arm 0.03). Histologically complete surgical resection following chemotherapy achieved ten (three pathological responses to chemotherapy) three (no responses). regimen resulted advantage chemotherapy. probability long-term residual disease is increased by this treatment. high seen support its use neoadjuvant setting.